Biogen Swings To A $20.6 Million Quarterly Loss On A $283.8 Million RayThera Charge
The 10-Q also discloses a Swiss tax-law change and an $84.5 million fee to exit a Texas lease.
Biogen, the biopharmaceutical company behind multiple sclerosis and spinal muscular atrophy drugs, posted a third-quarter net loss of $20.6 million, or $0.14 a share, after booking $283.8 million of acquired research expense, mostly for its RayThera purchase. The quarterly report filed Wednesday also shows a Swiss tax-law change and a Texas lease buyout.
The RayThera charge
Biogen completed the RayThera acquisition on August 6 with a $225.0 million upfront cash payment, expensed immediately because the deal was treated as an asset purchase. Milestones could add $275.0 million (development) and $500.0 million (regulatory).
Revenue still grew. Total revenue was $2,804.1 million against $2,534.7 million a year earlier, and the earnings release put adjusted diluted earnings at $2.62 a share. The company raised the low end of its full-year adjusted earnings guidance to a range of $12.20 to $13.00, from $12.00 to $13.00.
A tax rate of negative 128.5%
Biogen booked $11.6 million of tax expense on a $9.0 million pretax loss, an effective rate of (128.5)%. The filing attributes the swing mainly to the non-deductible RayThera charge, partly offset by a decrease in valuation allowances on Swiss loss carryforwards "following a tax law change during the quarter." The Swiss effect carries no dollar figure.
The prior quarter's 10-Q showed a 26.4% rate and no mention of the Swiss change.
Paying $84.5 million to leave Plano
In September, Biogen exited its Plano, Texas, Reata building lease, paying about $84.5 million plus $16.3 million of rent over 12 months.
The company wrote off $143.6 million of lease liabilities and about $53.4 million of right-of-use assets, leaving a pre-tax loss of about $10.6 million. It had already booked a $52.9 million impairment on the lease in late 2025.
Milestone debts move closer
Contingent consideration liabilities total $273.9 million, of which $152.4 million is now classed short-term. The expected timing of milestone achievement moved to 2027-2028, from 2028-2030 at year-end.
The restructuring reserve stood at $66.8 million at September 30, up from $35.9 million at June 30, as severance and Apellis integration costs continue. Biogen closed the Apellis acquisition in May, adding two eye and kidney drugs.
Biogen expects top-line data from its two late-stage litifilimab lupus trials in the first half of December 2026.
Sources
- 10-Q Filing — Biogen (BIIB) — SEC EDGAR
- 10-Q Filing — Biogen (BIIB), Q2 FY2026 filed 2026-07-29 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, exhibit991-q32026pressrele.htm) — Biogen, filed 2026-10-28 — SEC EDGAR
- Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report | Investor's Business Daily — investors.com
- Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat? — Yahoo Finance
- Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued — Yahoo Finance
- Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. — Barron's
- Biogen (BIIB) Stock May Be 45% Undervalued Despite Fresh Kidney Data — Yahoo Finance